ClinicalTrials.gg
RecruitingNCT07765797ProChangeUpdated Nov 16, 2026

Development and Validation of a Scale of Propensity for Change in Chronic Disease Prevention

An observational study in Atheroscleroses and Geriatric, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University Hospital, Toulouse · Observational

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
290
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Atherosclerosis with a site in France — 13 open to participants now, 23 under way, 10 of them phase 3. Atherosclerosis · France.

Planned enrollment
14th of 26
290 · median 291
Started
2026
with 3 others
Observational
26 of 75
6 open now
Primary completion
2028-04
later than 13 of 22 live
Registered
75th of 75
by date
Lead sponsor
3 of 75
University Hospital, Toulouse

Among the 75 studies in Atherosclerosis with a site in France, this one is the 14th largest by planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2026, is one of 26 observational ones, reaches primary completion later than 13 of the 22 other live ones, and was the 75th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

13 of the 75 studies in Atherosclerosis with a site in France are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 45 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Atherosclerosis with a site in France, or all of them as a file.
02

Study summary

Modifiable risk factors are estimated to account for 70% of cardiovascular diseases, 40% of Alzheimer's-type dementias, and 50% of type 2 diabetes cases. Numerous trials have evaluated interventions aimed at modifying these risk factors, whether through the promotion of healthy lifestyle choices (diet, physical activity, etc.) or specific activities (cognitive training, etc.). However, these trials have yielded inconsistent or modest results, potentially due to a failure to adopt the recommended lifestyle changes. To better tailor prevention interventions, it is therefore essential to have scales available that measure the barriers to and facilitators of lifestyle change.

The aim of this study is to develop and validate a Patient-Reported Outcome Measure (PROM) to assess the barriers to and facilitators of change following participation in a prevention program. The scale will be structured into three sub-scales (capability, opportunity, and motivation), administered one month after the prevention activity, and will distinguish between the adoption of new habits and the abandonment of existing ones.

03

Conditions studied

  • Atheroscleroses
  • Geriatric

Browse trials for

Keywords

  • prevention
  • gériatrics
  • risk factors
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients benefiting from a personalized prevention program in the context of geriatrics or cardiovascular diseases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant receiving a personalized prevention intervention through the frailty assessment day-hospital program, the Atherosclerosis Detection and Prevention Center (CDPA), or the Salutance program,
  • Participant who has received prevention advice aimed at improving their health in at least one of the following two areas: nutrition or physical activity,
  • Participant aged 45 or older (we are targeting a middle-aged to older population, as this group is the primary target for cardiovascular prevention initiatives and efforts to prevent pathological aging),

Exclusion criteria

Exclusion Criteria:

  • Participant unable to improve their lifestyle, according to the scales used in the study (participant with a maximum score on the ONAPS-PAQ scale and the food frequency score),
  • Participant without a postal or email address,
  • Participant with a of less than 5 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
290 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients benefiting from a personalized prevention initiative

    patients benefiting from a personalized prevention initiative aimed at improving nutritional or physical health

    Other: Scale development phase · Other: Beta testing phase · Other: Validation phase

Interventions

  • OtherScale development phase

    Questionnaire administered to patients to develop the scale's items and group them into subscales.

  • OtherBeta testing phase

    The scale will be administered to the patient in the form of a questionnaire for the testing phase.

  • OtherValidation phase

    The scale will be administered to patients in the form of questionnaires for the validation phase.

06

What researchers measure

Primary outcomes

  1. Development of the Prochange scale assessing barriers to and facilitators of lifestyle changes for the adoption of non-pharmacological strategies in the field of prevention.

    Development of a scale based on COSMIN criteria (COnsensus-based Standards for the selection of health Measurement INstruments), consisting of three subscales of 10 questions each.

    Time frame: 3 months after the inclusion

Secondary outcomes

  1. Measurement of the area under the curve of the Prochange scale for the prediction of an improvement in lifestyle at 3 months after the initiation of a preventive action

    Time frame: 3 months after the inclusion

  2. Comparison of the performance of the ProChange scale with that of pre-existing scales in predicting lifestyle change three months after the initiation of a prevention intervention.

    Time frame: 3 months after the inclusion

  3. Evaluation of the correlation between the score obtained on the ProChange scale one month after the prevention intervention and the extent of lifestyle modification three months after the initiation of the prevention intervention

    Time frame: 3 months after the inclusion

  4. Comparison of the ProChange scale with pre-existing scales

    Comparison of the ProChange scale with pre-existing scales in terms of the correlation between the score obtained on the scale one month after the prevention intervention and the extent of lifestyle change three months after the initiation of the prevention intervention.

    Time frame: 3 months after the inclusion

07

Study locations

1 of 1 sites recruiting
  • Service d'Epidémiologie Clinique et de Santé Publique CHU de Toulouse, Pôle Santé Publique et Médecine Sociale Faculté de Médecine, 37 allées Jules Guesde
    Toulouse, Oui 31000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2028, 18 months after the start.

Of 145 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's planned 18 months is below that.

Counting every sponsor, half of 170 studies reached it within 62 months; a quarter within 31 and three quarters within 153.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Sep 2026 → Oct 2026, primary completion Mar 2028 → Apr 2028 and completion Jun 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Aug 14, 2026
StartActual
Oct 30, 2026was Sep 2026
Primary completionEst.
Apr 30, 2028was Mar 2028
CompletionEst.
Jul 30, 2028was Jun 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Service d'Epidémiologie Clinique et de Santé Publique CHU de Toulouse, Pôle Santé Publique et Médecine Sociale Faculté de Médecine, 37 allées Jules Guesde is now Recruiting
Nov 16, 2026
Start date
Sep 1, 2026→Oct 30, 2026 (actual)
Nov 16, 2026
Primary completion
Mar 1, 2028→Apr 30, 2028
Nov 16, 2026
Study completion
Jun 1, 2028→Jul 30, 2028
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Service d'Epidémiologie Clinique et de Santé Publique CHU de Toulouse, Pôle Santé Publique et Médecine Sociale Faculté de Médecine, 37 allées Jules Guesde is now Recruiting
    Start date Sep 1, 2026→Oct 30, 2026 (now actual)
    Primary completion Mar 1, 2028→Apr 30, 2028
    Study completion Jun 1, 2028→Jul 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07765797
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Oct 30, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Jason SHOURICK, MD
Contact
shourick.j@chu-toulouse.fr
05 61 14 56 23 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion